Laura Fanning
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laura Fanning has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
J. Simon Bell
Faculty of Pharmacy and Pharmaceutical Sciences Centre for Medicine Use and Safety, Monash University Melbourne Victoria Australia
6 shared publications- Ian Chi Kei Wong
The University of Hong Kong
5 shared publications - Jenni Ilomäki
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University Parkville Victoria Australia
5 shared publications - Peteris Darzins
Eastern Health Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia
3 shared publications - Wallis C. Y. Lau
The University of Hong Kong
3 shared publications Atte Meretoja
2 shared publications
Latest Publications
- 17 December 2025
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
Formative Research in the Codesign of a Discrete Choice Experiment with Patients with Myasthenia Gravis: Selecting and Refining Attributes, Levels and Scenarios
Given the substantial burden faced by patients with myasthenia gravis (MG), including the disease itself, treatment-related side effects, the invasiveness of certain interventions and the time spent in seeking and receiving care, it is essential to understand patient preferences to inform resource allocation and enhance patients' quality of life. The aim of this study was to co-design the MG treatment choice tasks with patients for a discrete choice experiment (DCE) using a multi-stage, mixed-methods approach involving the nominal group technique (NGT) and focus groups. MG patients in Australia were invited to participate in two of eight 1-hour online sessions in July and August 2024. Each session included four to six patients and was facilitated by three researchers. Participants were presented with three MG scenarios: 'mild exacerbation', 'severe exacerbation' and 'maintenance phase'. During NGT sessions, patients shared their experiences with MG treatments, proposed DCE attributes and ranked their importance for each scenario. Attribute rankings were normalised to a 0-1 scale, averaged within each session and combined using a weighted mean adjusted for group size. The rankings were used to prioritise attributes for inclusion in DCEs. In subsequent focus groups, patients reviewed draft DCE scenario descriptions and provided feedback on the clarity and relevance of attribute descriptions and levels. Throughout the process, research team discussions were held to discuss clinical and methodological relevance of the emerging results. Nineteen patients with MG aged 35-82 years (12 females, 7 males) participated in four online NGT and four focus group sessions, identifying 31 attributes across treatment administration (n = 10), side effects (n = 16) and treatment outcomes (n = 5). Attribute rankings varied by scenario, with 'recommended by neurologist', health care workers' knowledge of the treatment' and 'easy access to treatment' being consistently top-ranked among treatment administration attributes. Side effects ranged broadly, from gastrointestinal issues to skin cancer. For treatment outcome attributes, 'chance to improve' was most highly ranked for mild and severe exacerbation scenarios, whereas 'risk of getting severely worse' and 'duration of effectiveness' were equally top-ranked for the maintenance scenario. Attribute rankings and patient perspectives were balanced with DCE methodological considerations and clinician input to finalise attributes for each scenario, including grouping similar side effects to describe a few attributes and retaining the 'cost to patient' attribute despite it being a low patient priority to allow trade-off analysis in the resulting choice data. A final list of seven attributes was selected for both the mild exacerbation and maintenance scenarios. Discussions from focus groups and research team deliberation further refined scenario descriptions and attribute levels to enhance relevance and clarity. This study reinforces the value of a blended and staged approach of combining NGT and focus group sessions with multidisciplinary research team discussions to shape the development of patient-centred research in DCE design.
- 17 December 2025
- Published by Springer Nature in The Patient - Patient-Centered Outcomes Research
Formative Research in the Codesign of a Discrete Choice Experiment with Patients with Myasthenia Gravis: Selecting and Refining Attributes, Levels and Scenarios
Given the substantial burden faced by patients with myasthenia gravis (MG), including the disease itself, treatment-related side effects, the invasiveness of certain interventions and the time spent in seeking and receiving care, it is essential to understand patient preferences to inform resource allocation and enhance patients' quality of life. The aim of this study was to co-design the MG treatment choice tasks with patients for a discrete choice experiment (DCE) using a multi-stage, mixed-methods approach involving the nominal group technique (NGT) and focus groups. MG patients in Australia were invited to participate in two of eight 1-hour online sessions in July and August 2024. Each session included four to six patients and was facilitated by three researchers. Participants were presented with three MG scenarios: 'mild exacerbation', 'severe exacerbation' and 'maintenance phase'. During NGT sessions, patients shared their experiences with MG treatments, proposed DCE attributes and ranked their importance for each scenario. Attribute rankings were normalised to a 0-1 scale, averaged within each session and combined using a weighted mean adjusted for group size. The rankings were used to prioritise attributes for inclusion in DCEs. In subsequent focus groups, patients reviewed draft DCE scenario descriptions and provided feedback on the clarity and relevance of attribute descriptions and levels. Throughout the process, research team discussions were held to discuss clinical and methodological relevance of the emerging results. Nineteen patients with MG aged 35-82 years (12 females, 7 males) participated in four online NGT and four focus group sessions, identifying 31 attributes across treatment administration (n = 10), side effects (n = 16) and treatment outcomes (n = 5). Attribute rankings varied by scenario, with 'recommended by neurologist', health care workers' knowledge of the treatment' and 'easy access to treatment' being consistently top-ranked among treatment administration attributes. Side effects ranged broadly, from gastrointestinal issues to skin cancer. For treatment outcome attributes, 'chance to improve' was most highly ranked for mild and severe exacerbation scenarios, whereas 'risk of getting severely worse' and 'duration of effectiveness' were equally top-ranked for the maintenance scenario. Attribute rankings and patient perspectives were balanced with DCE methodological considerations and clinician input to finalise attributes for each scenario, including grouping similar side effects to describe a few attributes and retaining the 'cost to patient' attribute despite it being a low patient priority to allow trade-off analysis in the resulting choice data. A final list of seven attributes was selected for both the mild exacerbation and maintenance scenarios. Discussions from focus groups and research team deliberation further refined scenario descriptions and attribute levels to enhance relevance and clarity. This study reinforces the value of a blended and staged approach of combining NGT and focus group sessions with multidisciplinary research team discussions to shape the development of patient-centred research in DCE design.
- Open Access
- 16 September 2020
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 29 (12) , 1550-1561
Gastrointestinal bleeding risk with rivaroxaban vs aspirin in atrial fibrillation: A multinational study
Purpose: Comparative gastrointestinal bleeding (GIB) risk between rivaroxaban and low‐dose aspirin is unknown in patients with atrial fibrillation (AF). This study investigated GIB risk with rivaroxaban vs aspirin among two separate AF cohorts in Hong Kong and the United Kingdom, using a common protocol approach.Methods: This was a population‐based cohort study using separate data from the Clinical Data Analysis and Reporting System (CDARS) of the Hong Kong Hospital Authority (2010‐2018) and The Health Improvement Network (THIN) database in the United Kingdom (2011‐2017). Patients with AF newly prescribed aspirin or rivaroxaban were included. Cox proportional hazards regression was used to compare GIB risks for rivaroxaban vs aspirin, accounting for confounders using propensity score fine stratification approach.Results: In CDARS, 29 213 patients were included; n = 1052 (rivaroxaban), n = 28 161 (aspirin). Crude GIB event rates per 100 patient‐years in CDARS were 3.0 (aspirin) and 2.6 (rivaroxaban). No difference in GIB risk was observed between rivaroxaban and aspirin overall (HR = 1.04, 95%CI = 0.76‐1.42), and in dose‐stratified analyses (HR = 1.21, 95%CI = 0.84‐1.74 [20 mg/day]; HR = 0.80, 95%CI = 0.44‐1.45 [≤15 mg/day]). In THIN, 11 549 patients were included, n = 3496 (rivaroxaban) and n = 8053 (aspirin). Crude GIB event rates were 1.3 (aspirin) and 2.4 (rivaroxaban) per 100 patient‐years. No difference in GIB risk was observed between rivaroxaban and aspirin overall (HR = 1.40, 95%CI = 1.00‐1.98) and low‐dose rivaroxaban (≤15 mg/day) (HR = 1.00, 95%CI = 0.56‐1.30), but increased GIB risk was observed for rivaroxaban 20 mg/day vs aspirin (HR = 1.57, 95%CI = 1.08‐2.29).Conclusion: In patients with AF, GIB risk was comparable between aspirin and rivaroxaban ≤15 mg/day. GIB risk for rivaroxaban 20 mg/day vs aspirin remains uncertain and warrants further investigation.
- 16 September 2020
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 29 (12) , 1550-1561
Open AccessGastrointestinal bleeding risk with rivaroxaban vs aspirin in atrial fibrillation: A multinational study
Purpose: Comparative gastrointestinal bleeding (GIB) risk between rivaroxaban and low‐dose aspirin is unknown in patients with atrial fibrillation (AF). This study investigated GIB risk with rivaroxaban vs aspirin among two separate AF cohorts in Hong Kong and the United Kingdom, using a common protocol approach.Methods: This was a population‐based cohort study using separate data from the Clinical Data Analysis and Reporting System (CDARS) of the Hong Kong Hospital Authority (2010‐2018) and The Health Improvement Network (THIN) database in the United Kingdom (2011‐2017). Patients with AF newly prescribed aspirin or rivaroxaban were included. Cox proportional hazards regression was used to compare GIB risks for rivaroxaban vs aspirin, accounting for confounders using propensity score fine stratification approach.Results: In CDARS, 29 213 patients were included; n = 1052 (rivaroxaban), n = 28 161 (aspirin). Crude GIB event rates per 100 patient‐years in CDARS were 3.0 (aspirin) and 2.6 (rivaroxaban). No difference in GIB risk was observed between rivaroxaban and aspirin overall (HR = 1.04, 95%CI = 0.76‐1.42), and in dose‐stratified analyses (HR = 1.21, 95%CI = 0.84‐1.74 [20 mg/day]; HR = 0.80, 95%CI = 0.44‐1.45 [≤15 mg/day]). In THIN, 11 549 patients were included, n = 3496 (rivaroxaban) and n = 8053 (aspirin). Crude GIB event rates were 1.3 (aspirin) and 2.4 (rivaroxaban) per 100 patient‐years. No difference in GIB risk was observed between rivaroxaban and aspirin overall (HR = 1.40, 95%CI = 1.00‐1.98) and low‐dose rivaroxaban (≤15 mg/day) (HR = 1.00, 95%CI = 0.56‐1.30), but increased GIB risk was observed for rivaroxaban 20 mg/day vs aspirin (HR = 1.57, 95%CI = 1.08‐2.29).Conclusion: In patients with AF, GIB risk was comparable between aspirin and rivaroxaban ≤15 mg/day. GIB risk for rivaroxaban 20 mg/day vs aspirin remains uncertain and warrants further investigation.
- 1 August 2020
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 21 (8) , 1058-1064.e6
Safety and Effectiveness of Direct Oral Anticoagulants vs Warfarin in People With Atrial Fibrillation and Dementia
- 1 August 2020
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 21 (8) , 1058-1064.e6
Safety and Effectiveness of Direct Oral Anticoagulants vs Warfarin in People With Atrial Fibrillation and Dementia
- 15 October 2019
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 71 (4) , 1375-1378
Prevalence, Safety, and Effectiveness of Oral Anticoagulant Use in People with and without Dementia or Cognitive Impairment: A Systematic Review and Meta-Analysis
- 15 October 2019
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 71 (4) , 1375-1378
Prevalence, Safety, and Effectiveness of Oral Anticoagulant Use in People with and without Dementia or Cognitive Impairment: A Systematic Review and Meta-Analysis
- 3 August 2019
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 70 (3) , 733-745
Trends and Predictors of Oral Anticoagulant Use in People with Alzheimer’s Disease and the General Population in Australia
Background: People with Alzheimer’s disease (AD) are less likely to use oral anticoagulants than people without AD. Objective: We investigated incidence and prevalence of warfarin and direct oral anticoagulant (DOAC) use, and determined predictors of
- 3 August 2019
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 70 (3) , 733-745
Trends and Predictors of Oral Anticoagulant Use in People with Alzheimer’s Disease and the General Population in Australia
Background: People with Alzheimer’s disease (AD) are less likely to use oral anticoagulants than people without AD. Objective: We investigated incidence and prevalence of warfarin and direct oral anticoagulant (DOAC) use, and determined predictors of
- 1 May 2019
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 73 (5) , 429-439
A Cost-Effectiveness Analysis Comparing Clinical Decision Rules PECARN, CATCH, and CHALICE With Usual Care for the Management of Pediatric Head Injury
- 1 May 2019
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 73 (5) , 429-439
A Cost-Effectiveness Analysis Comparing Clinical Decision Rules PECARN, CATCH, and CHALICE With Usual Care for the Management of Pediatric Head Injury
- Open Access
- 20 July 2018
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 65 (2) , 489-517
Prevalence, Safety, and Effectiveness of Oral Anticoagulant Use in People with and without Dementia or Cognitive Impairment: A Systematic Review and Meta-Analysis
Background: Differences in management and outcomes of oral anticoagulant (OAC) use may exist for people with and without dementia or cognitive impairment (CI). Objective: To systematically review the prevalence and safety and effectiveness outcomes of OAC use in people with and without dementia or CI. Methods: MEDLINE, EMBASE, and CINAHL were searched for studies reporting prevalence or safety and effectiveness outcomes of OAC use for people with and without dementia, published between 2000 to September 2017. Study selection, data extraction, and quality assessment were performed by two reviewers. Results: studies met pre-specified inclusion criteria (21 prevalence studies, 6 outcomes studies). People with dementia had 52% lower odds of receiving OAC compared to people without dementia. Mean OAC prevalence was 32% for people with dementia, compared to 48% without dementia. There was no difference in the composite outcome of embolic events, myocardial infarction, and all-cause death between dementia and non-dementia groups (adjusted hazard ratio (HR) 0.72, 95% CI, 0.45–1.14, p = 0.155). Bleeding rate was lower for people without dementia (HR 0.56, 95% CI, 0.37–0.85). Adverse warfarin events were more common for residents of long-term care with dementia (adjusted incidence rate ratio 1.48, 95% CI, 1.20–1.82). Community-dwelling people with dementia treated with warfarin had poorer anticoagulation control than those without dementia (mean time in therapeutic range (TTR) % ±SD, 38±26 (dementia), 61±27 (no dementia), p < 0.0001). Conclusion: A lower proportion of people with dementia received oral anticoagulation compared with people without dementia. People with dementia had higher bleeding risk and poorer anticoagulation control when treated with warfarin.
- 20 July 2018
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 65 (2) , 489-517
Open AccessPrevalence, Safety, and Effectiveness of Oral Anticoagulant Use in People with and without Dementia or Cognitive Impairment: A Systematic Review and Meta-Analysis
Background: Differences in management and outcomes of oral anticoagulant (OAC) use may exist for people with and without dementia or cognitive impairment (CI). Objective: To systematically review the prevalence and safety and effectiveness outcomes of OAC use in people with and without dementia or CI. Methods: MEDLINE, EMBASE, and CINAHL were searched for studies reporting prevalence or safety and effectiveness outcomes of OAC use for people with and without dementia, published between 2000 to September 2017. Study selection, data extraction, and quality assessment were performed by two reviewers. Results: studies met pre-specified inclusion criteria (21 prevalence studies, 6 outcomes studies). People with dementia had 52% lower odds of receiving OAC compared to people without dementia. Mean OAC prevalence was 32% for people with dementia, compared to 48% without dementia. There was no difference in the composite outcome of embolic events, myocardial infarction, and all-cause death between dementia and non-dementia groups (adjusted hazard ratio (HR) 0.72, 95% CI, 0.45–1.14, p = 0.155). Bleeding rate was lower for people without dementia (HR 0.56, 95% CI, 0.37–0.85). Adverse warfarin events were more common for residents of long-term care with dementia (adjusted incidence rate ratio 1.48, 95% CI, 1.20–1.82). Community-dwelling people with dementia treated with warfarin had poorer anticoagulation control than those without dementia (mean time in therapeutic range (TTR) % ±SD, 38±26 (dementia), 61±27 (no dementia), p < 0.0001). Conclusion: A lower proportion of people with dementia received oral anticoagulation compared with people without dementia. People with dementia had higher bleeding risk and poorer anticoagulation control when treated with warfarin.
- Open Access
- 18 May 2018
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 9 (8) , 425-438
Validity of electronic hospital discharge prescription records as a source of medication data for pharmacoepidemiological research
The advent of hospital electronic medical records (EMRs) with electronic prescribing provides considerable opportunity for pharmacoepidemiological research. However, validity of EMR prescribing data for research purposes is not well established. Validity concerns the percentage of cases in which medications and characteristics (name, type, formulation, dose) are true when verified with an independent data source. This study evaluated the validity of EMR discharge prescription data within the Eastern Health hospital network in Melbourne, Australia. A random sample of patients were selected who had a diagnosis of atrial fibrillation (AF) and were prescribed at least five medications. Prescription records from 2012 to 2015 were compared with pharmacy dispensing and hospital medical records (reference standards). Medication name, dose, directions and route of administration were compared. Discrepancies between data sources were categorized as omissions, additions, discrepancies in dose, medication form or route of administration or discrepancies in reordering. Sensitivities and 95% confidence intervals (CIs) for intended medication exposure were estimated for therapeutic classes. A total of 5724 prescription orders for 479 patients for whom reference standards were available were included. There were 163 discrepancies (2.8%) between prescription records and reference standards. Additions were the most common data discrepancy (n = 65; ~1.1% of total prescriptions evaluated), followed by discrepancies in reordering (n = 34; 0.59%). Sensitivities for intended patient exposure to a medication for each therapeutic class at the first level of the Anatomical Therapeutic Chemical (ATC) classification system were between 97% and 100%. The genitourinary system and sex hormone level of the ATC system demonstrated the lowest sensitivity, (97.3%; 95% CI 92.0%–100%) and the cardiovascular system level demonstrated the highest sensitivity (99.9%; 95% CI 99.7%–100%). EMR discharge prescription records for patients with AF are a valid information source for conducting pharmacoepidemiological research within Eastern Health in Melbourne, Australia. Further studies in different regions, countries and patient cohorts are required to establish validity of hospital EMR prescription records for pharmacoepidemiological research.
- 18 May 2018
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 9 (8) , 425-438
Open AccessValidity of electronic hospital discharge prescription records as a source of medication data for pharmacoepidemiological research
The advent of hospital electronic medical records (EMRs) with electronic prescribing provides considerable opportunity for pharmacoepidemiological research. However, validity of EMR prescribing data for research purposes is not well established. Validity concerns the percentage of cases in which medications and characteristics (name, type, formulation, dose) are true when verified with an independent data source. This study evaluated the validity of EMR discharge prescription data within the Eastern Health hospital network in Melbourne, Australia. A random sample of patients were selected who had a diagnosis of atrial fibrillation (AF) and were prescribed at least five medications. Prescription records from 2012 to 2015 were compared with pharmacy dispensing and hospital medical records (reference standards). Medication name, dose, directions and route of administration were compared. Discrepancies between data sources were categorized as omissions, additions, discrepancies in dose, medication form or route of administration or discrepancies in reordering. Sensitivities and 95% confidence intervals (CIs) for intended medication exposure were estimated for therapeutic classes. A total of 5724 prescription orders for 479 patients for whom reference standards were available were included. There were 163 discrepancies (2.8%) between prescription records and reference standards. Additions were the most common data discrepancy (n = 65; ~1.1% of total prescriptions evaluated), followed by discrepancies in reordering (n = 34; 0.59%). Sensitivities for intended patient exposure to a medication for each therapeutic class at the first level of the Anatomical Therapeutic Chemical (ATC) classification system were between 97% and 100%. The genitourinary system and sex hormone level of the ATC system demonstrated the lowest sensitivity, (97.3%; 95% CI 92.0%–100%) and the cardiovascular system level demonstrated the highest sensitivity (99.9%; 95% CI 99.7%–100%). EMR discharge prescription records for patients with AF are a valid information source for conducting pharmacoepidemiological research within Eastern Health in Melbourne, Australia. Further studies in different regions, countries and patient cohorts are required to establish validity of hospital EMR prescription records for pharmacoepidemiological research.